About MedGenome

MedGenome was established in 2013 with a vision to make genomic healthcare affordable, accessible, and equitable, and reduce the country’s rising disease burden. We enable omics led early diagnosis and targeted disease management to improve healthcare outcomes. Over the past decade, MedGenome has served more than 10 lakh patients by building awareness about the impact of early intervention and empowering healthcare providers with, actionable insights across critical disease areas such as rare diseases, oncology, and reproductive healthcare.

Science, innovation, quality, and technology have been at the core of the work we do. We operate South Asia’s largest CAP-accredited multiomics laboratory equipped with the latest high-throughput sequencing technology and a proprietary analytics platform in India. Our growing relationships with over 24000 clinicians, 8000 hospitals, and several leading pharma partners are built on more than a decade of trust, quality, and scientific excellence. Innovation lies at the heart of everything we do as we continue to adapt to the evolving healthcare needs and improve our understanding of complex diseases. Our quality-first approach is reinforced by our commitment to research-backed, validated studies for every new test we launch. Over the past decade, MedGenome has brought several in house developed firsts such as clinical exome sequencing, high-resolution HLA typing, NIPT validated for the Indian population, liquid biopsy, saliva-based whole-genome sequencing for drug-resistant TB diagnosis, India’s first polygenic risk score–based test to assess the genetic risk of developing heart disease, and many more.